Home / 2019 (page 88)

Yearly Archives: 2019

Large-Scale Study Clarifies Polycystic Ovary Syndrome Diagnosis

Diabetes in Control is pleased to bring you an exclusive interview with Dr. Andrea Dunaif, the Lillian and Henry M. Stratton Professor of Molecular Medicine and Chief of the J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dunaif is an internationally recognized expert in endocrinology and women’s health. Her research on polycystic ovary syndrome (PCOS), the most common hormonal disorder of reproductive-age women, has shown that it is a leading risk factor for type 2 diabetes mellitus. Further, this research has revolutionized the treatment of PCOS with insulin-sensitizing drugs.

Read More »

Defining Obesity

Is obesity a disease or a lifestyle choice? Follow the link to share your opinion and see what your colleagues think.

Read More »

Type 2 Medication Risks

Which of the following commonly prescribed drugs to treat type 2 diabetes carries a high risk of cardiovascular events, including heart attack, stroke, heart failure, or amputation, according to a recent study?

- Basal insulin
- Biguanides
- Meglitinide derivatives
- Alpha-glucosidase inhibitors
- Glucagon-like peptide–1 (GLP-1) agonists
- Dipeptidyl peptidase IV (DPP-4) Inhibitors
- Selective sodium-glucose transporter-2 (SGLT-2) inhibitors

Follow the link for the answer.

Read More »